NV
New Vernon Capital Holdings II LLC
13F filer · CIK 0001512538Reported Aug 14, 2026
13F portfolio value$181MU.S. long equity reported on 13F
Positions57Not reported new · Not reported closed
Net flow last quarterNot reportedBuys minus sells
Top 10 positions weight38.1%Concentration
Holdings
13F · last 4 quarters freeScroll for earlier quarters
| Company | Value | % of portfolio | % of company | POSITION CHANGE qoq % | First reported |
|---|---|---|---|---|---|
| Q2 2026Reported Aug 14, 202657 positions | |||||
| $24.4M | 13.47% | 0.00% | Not reported | Q3 2020 | |
| $16.5M | 9.11% | Not reported | +47.3% | Q2 2014 | |
| $10.3M | 5.70% | 0.00% | Not reported | Q3 2015 | |
| $6.57M | 3.62% | 0.00% | Not reported | Q1 2018 | |
| $5.26M | 2.90% | 0.00% | Not reported | Q4 2020 | |
| $2.31M | 1.27% | 0.00% | Not reported | Q3 2024 | |
| $1.75M | 0.96% | 0.00% | Not reported | Q1 2018 | |
| $797K | 0.44% | 0.00% | Not reported | Q3 2024 | |
| $572K | 0.32% | 0.00% | Not reported | Q4 2025 | |
| $519K | 0.29% | 0.00% | Not reported | Q4 2025 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $425K | 0.23% | 0.01% | 0.0% | Q1 2024 |
| $421K | 0.23% | 0.00% | Not reported | Q4 2025 | |
| $387K | 0.21% | 0.00% | New | Q2 2026 | |
| $348K | 0.19% | 0.01% | Not reported | Q1 2026 | |
| $346K | 0.19% | 0.00% | New | Q2 2026 | |
| $320K | 0.18% | 0.01% | Not reported | Q2 2022 | |
| $317K | 0.17% | 0.00% | Not reported | Q1 2024 | |
| $299K | 0.16% | 0.00% | Not reported | Q3 2025 | |
| $298K | 0.16% | 0.02% | Not reported | Q1 2018 | |
| $296K | 0.16% | 0.01% | Not reported | Q2 2023 | |
| $290K | 0.16% | 0.01% | Not reported | Q1 2024 | |
| $289K | 0.16% | 0.00% | Not reported | Q3 2023 | |
| $273K | 0.15% | 0.01% | Not reported | Q3 2022 | |
| $261K | 0.14% | 0.01% | Not reported | Q4 2025 | |
| $261K | 0.14% | 0.01% | Not reported | Q1 2026 | |
| $258K | 0.14% | 0.01% | Not reported | Q1 2026 | |
| $250K | 0.14% | 0.01% | Not reported | Q2 2022 | |
| $239K | 0.13% | 0.00% | Not reported | Q3 2023 | |
| $238K | 0.13% | 0.00% | Not reported | Q2 2018 | |
| $234K | 0.13% | 0.00% | Not reported | Q3 2020 | |
| $233K | 0.13% | 0.00% | Not reported | Q4 2025 | |
| $232K | 0.13% | 0.02% | Not reported | Q1 2026 | |
| $219K | 0.12% | 0.00% | Not reported | Q3 2025 | |
| $210K | 0.12% | 0.00% | Not reported | Q4 2025 | |
| $207K | 0.11% | 0.00% | Not reported | Q3 2018 | |
| $193K | 0.11% | 0.02% | Not reported | Q1 2024 | |
| $165K | 0.09% | 0.01% | Not reported | Q4 2023 | |
| $162K | 0.09% | 0.00% | Not reported | Q1 2025 | |
| $145K | 0.08% | 0.00% | Not reported | Q4 2025 | |
| $143K | 0.08% | 0.00% | Not reported | Q1 2018 | |
| $140K | 0.08% | 0.00% | Not reported | Q4 2024 | |
| $125K | 0.07% | 0.00% | Not reported | Q1 2026 | |
| $122K | 0.07% | 0.00% | +93.4% | Q2 2025 | |
| $119K | 0.07% | 0.00% | +795.1% | Q4 2025 | |
| $111K | 0.06% | 0.00% | Not reported | Q3 2013 | |
| $111K | 0.06% | 0.00% | +1100.1% | Q4 2025 | |
| $108K | 0.06% | 0.00% | Not reported | Q2 2025 | |
| $100K | 0.06% | Not reported | +228.1% | Q4 2025 | |
| $97.9K | 0.05% | 0.00% | +23.5% | Q2 2025 | |
| $92.7K | 0.05% | 0.00% | Not reported | Q2 2025 | |
| Q1 2026Reported May 15, 202663 positions | |||||
| $17.3M | 12.76% | 0.00% | Not reported | Q3 2020 | |
| $10M | 7.38% | Not reported | -42.8% | Q2 2014 | |
| $2.25M | 1.66% | 0.00% | -50.5% | Q1 2018 | |
| $2.25M | 1.66% | 0.00% | -12.9% | Q3 2024 | |
| $690K | 0.51% | 0.00% | Not reported | Q4 2025 | |
| $628K | 0.46% | 0.00% | -13.6% | Q3 2024 | |
| $472K | 0.35% | 0.00% | Not reported | Q4 2025 | |
| $441K | 0.33% | 0.00% | Not reported | Q4 2025 | |
| $340K | 0.25% | 0.00% | Not reported | Q1 2025 | |
| $337K | 0.25% | 0.01% | Not reported | Q1 2024 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $335K | 0.25% | 0.01% | Not reported | Q1 2024 |
| $306K | 0.23% | 0.02% | Not reported | Q1 2018 | |
| $304K | 0.22% | 0.02% | New | Q1 2026 | |
| $288K | 0.21% | 0.00% | Not reported | Q4 2025 | |
| $283K | 0.21% | 484200.00% | Not reported | Q2 2023 | |
| $261K | 0.19% | 0.00% | Not reported | Q1 2025 | |
| $260K | 0.19% | 0.01% | +100.0% | Q2 2025 | |
| $250K | 0.18% | 0.01% | Not reported | Q2 2023 | |
| $250K | 0.18% | 0.00% | Not reported | Q3 2025 | |
| $241K | 0.18% | 0.00% | Not reported | Q3 2023 | |
| $239K | 0.18% | 0.01% | New | Q1 2026 | |
| $237K | 0.17% | 0.01% | Not reported | Q2 2022 | |
| $226K | 0.17% | 0.00% | +0.3% | Q3 2023 | |
| $225K | 0.17% | 0.01% | Not reported | Q4 2024 | |
| $224K | 0.17% | 0.01% | Not reported | Q4 2025 | |
| $219K | 0.16% | 0.01% | New | Q1 2026 | |
| $218K | 0.16% | 0.01% | Not reported | Q2 2022 | |
| $217K | 0.16% | 0.00% | Not reported | Q1 2024 | |
| $215K | 0.16% | 0.00% | Not reported | Q3 2018 | |
| $212K | 0.16% | 0.00% | Not reported | Q3 2025 | |
| $208K | 0.15% | 0.00% | Not reported | Q2 2018 | |
| $205K | 0.15% | 0.01% | New | Q1 2026 | |
| $201K | 0.15% | 0.01% | Not reported | Q3 2022 | |
| $200K | 0.15% | 0.00% | New | Q1 2026 | |
| $189K | 0.14% | 0.00% | Not reported | Q3 2020 | |
| $177K | 0.13% | 0.02% | Not reported | Q1 2024 | |
| $176K | 0.13% | 0.00% | Not reported | Q3 2013 | |
| $171K | 0.13% | 0.00% | Not reported | Q4 2025 | |
| $156K | 0.12% | 0.00% | +100.0% | Q2 2025 | |
| $148K | 0.11% | 0.00% | New | Q1 2026 | |
| $137K | 0.10% | 0.01% | Not reported | Q3 2025 | |
| $128K | 0.09% | 0.00% | Not reported | Q2 2025 | |
| $127K | 0.09% | 0.01% | Not reported | Q4 2023 | |
| $125K | 0.09% | 0.00% | Not reported | Q4 2025 | |
| $123K | 0.09% | 0.00% | Not reported | Q1 2025 | |
| $119K | 0.09% | 0.00% | Not reported | Q1 2018 | |
| $105K | 0.08% | 0.00% | +100.0% | Q2 2025 | |
| $103K | 0.08% | 0.00% | Not reported | Q4 2024 | |
| $103K | 0.08% | 0.00% | Not reported | Q2 2025 | |
| $103K | 0.08% | 0.00% | Not reported | Q2 2025 | |
| Q4 2025Reported Feb 17, 202672 positions | |||||
| $25.5M | 12.09% | 0.00% | Not reported | Q3 2015 | |
| $20.1M | 9.54% | Not reported | -18.0% | Q2 2014 | |
| $15.6M | 7.37% | 0.00% | Not reported | Q3 2020 | |
| $6M | 2.84% | 0.01% | Not reported | Q1 2018 | |
| $4.29M | 2.03% | Not reported | New | Q4 2025 | |
| $2.33M | 1.11% | 0.00% | Not reported | Q3 2024 | |
| $863K | 0.41% | 0.00% | Not reported | Q3 2024 | |
| $757K | 0.36% | Not reported | -66.3% | Q4 2013 | |
| $515K | 0.24% | 0.00% | New | Q4 2025 | |
| $511K | 0.24% | 0.00% | Not reported | Q1 2025 | |
| $497K | 0.24% | 0.01% | Not reported | Q3 2022 | |
| $463K | 0.22% | 0.00% | New | Q4 2025 | |
| $443K | 0.21% | 0.00% | New | Q4 2025 | |
| $440K | 0.21% | 0.00% | -22.4% | Q1 2025 | |
| $404K | 0.19% | 0.01% | Not reported | Q1 2025 | |
| $380K | 0.18% | 0.01% | Not reported | Q1 2025 | |
| $361K | 0.17% | 0.01% | -42.5% | Q4 2024 | |
| $354K | 0.17% | 484200.00% | Not reported | Q2 2023 | |
| TTGNATegna Inc | $353K | 0.17% | Not reported | Not reported | Q1 2018 |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $316K | 0.15% | 0.01% | Not reported | Q1 2024 |
| $296K | 0.14% | 0.00% | Not reported | Q1 2025 | |
| $291K | 0.14% | 0.00% | New | Q4 2025 | |
| $279K | 0.13% | 0.00% | -0.2% | Q3 2025 | |
| $267K | 0.13% | 0.00% | Not reported | Q1 2025 | |
| $266K | 0.13% | 0.01% | Not reported | Q1 2024 | |
| $262K | 0.12% | 0.02% | Not reported | Q1 2018 | |
| $262K | 0.12% | 0.00% | Not reported | Q3 2024 | |
| $250K | 0.12% | 0.01% | Not reported | Q2 2023 | |
| $249K | 0.12% | 0.00% | +51.1% | Q3 2023 | |
| $248K | 0.12% | 0.01% | Not reported | Q2 2022 | |
| $247K | 0.12% | 0.02% | Not reported | Q1 2024 | |
| $241K | 0.11% | 0.00% | Not reported | Q2 2018 | |
| $238K | 0.11% | 0.00% | Not reported | Q3 2013 | |
| $238K | 0.11% | 0.01% | New | Q4 2025 | |
| $238K | 0.11% | 0.01% | +646.7% | Q2 2022 | |
| $232K | 0.11% | 0.02% | Not reported | Q3 2024 | |
| $229K | 0.11% | 0.00% | Not reported | Q1 2018 | |
| $228K | 0.11% | 0.00% | +123.4% | Q1 2018 | |
| $223K | 0.11% | 0.00% | -56.7% | Q4 2024 | |
| $219K | 0.10% | 0.00% | Not reported | Q3 2025 | |
| $213K | 0.10% | 0.01% | Not reported | Q1 2025 | |
| $212K | 0.10% | Not reported | New | Q4 2025 | |
| $199K | 0.09% | 0.00% | Not reported | Q3 2020 | |
| $196K | 0.09% | 0.00% | Not reported | Q3 2023 | |
| $190K | 0.09% | 0.00% | -0.6% | Q1 2024 | |
| $186K | 0.09% | 0.01% | -44.6% | Q4 2024 | |
| $180K | 0.09% | 0.00% | Not reported | Q3 2018 | |
| $178K | 0.08% | 0.00% | New | Q4 2025 | |
| $170K | 0.08% | 0.01% | Not reported | Q4 2023 | |
| $169K | 0.08% | 0.01% | -0.5% | Q3 2025 | |
| Q3 2025Reported Nov 14, 202562 positions | |||||
| $24.9M | 11.47% | Not reported | Not reported | Q2 2014 | |
| $23.8M | 10.97% | 0.00% | Not reported | Q3 2015 | |
| $14.3M | 6.58% | 0.00% | Not reported | Q3 2020 | |
| $5.48M | 2.52% | 0.01% | -50.2% | Q1 2018 | |
| $2.81M | 1.29% | 0.01% | Not reported | Q2 2020 | |
| $2.55M | 1.18% | Not reported | Not reported | Q4 2013 | |
| $2.38M | 1.10% | 0.00% | Not reported | Q2 2020 | |
| $2.17M | 1.00% | 0.00% | Not reported | Q3 2024 | |
| $764K | 0.35% | 0.00% | Not reported | Q3 2024 | |
| $742K | 0.34% | 0.00% | Not reported | Q1 2025 | |
| $543K | 0.25% | 0.00% | Not reported | Q1 2025 | |
| $478K | 0.22% | 0.01% | Not reported | Q4 2024 | |
| $437K | 0.20% | 0.00% | Not reported | Q4 2024 | |
| $412K | 0.19% | 0.02% | Not reported | Q4 2024 | |
| TTGNATegna Inc | $369K | 0.17% | Not reported | Not reported | Q1 2018 |
| $363K | 0.17% | 0.00% | Not reported | Q1 2025 | |
| $342K | 0.16% | 0.00% | -21.6% | Q4 2023 | |
| $341K | 0.16% | 0.01% | Not reported | Q1 2024 | |
| $321K | 0.15% | 0.02% | Not reported | Q3 2023 | |
| $316K | 0.15% | 0.01% | Not reported | Q1 2025 | |
| $310K | 0.14% | 0.00% | Not reported | Q1 2025 | |
| $305K | 0.14% | 484200.00% | Not reported | Q2 2023 | |
| $295K | 0.14% | 0.00% | -51.5% | Q2 2018 | |
| $295K | 0.14% | 0.02% | Not reported | Q3 2024 | |
| $269K | 0.12% | 0.02% | Not reported | Q2 2025 | |
| CPCPRXCatalyst Pharmaceuticals, Inc. | $266K | 0.12% | 0.01% | Not reported | Q1 2024 |
| $266K | 0.12% | 0.01% | -52.8% | Q3 2024 | |
| $263K | 0.12% | 0.01% | Not reported | Q2 2022 | |
| $252K | 0.12% | 0.00% | Not reported | Q1 2025 | |
| $248K | 0.11% | 0.00% | Not reported | Q3 2024 | |
| $239K | 0.11% | 0.02% | Not reported | Q1 2018 | |
| $231K | 0.11% | 0.00% | +22.3% | Q1 2018 | |
| $229K | 0.11% | 0.00% | New | Q3 2025 | |
| $226K | 0.10% | 0.00% | New | Q3 2025 | |
| $210K | 0.10% | 0.01% | +70.2% | Q1 2025 | |
| $196K | 0.09% | 0.01% | Not reported | Q2 2023 | |
| $190K | 0.09% | 0.00% | Not reported | Q1 2018 | |
| $187K | 0.09% | 0.02% | Not reported | Q1 2024 | |
| $180K | 0.08% | 0.01% | New | Q3 2025 | |
| $174K | 0.08% | 0.01% | New | Q3 2025 | |
| $161K | 0.07% | 0.00% | Not reported | Q3 2023 | |
| $156K | 0.07% | 0.00% | Not reported | Q3 2018 | |
| $147K | 0.07% | 0.00% | Not reported | Q1 2024 | |
| $138K | 0.06% | 0.00% | Not reported | Q3 2024 | |
| $125K | 0.06% | 0.01% | -69.1% | Q4 2023 | |
| $120K | 0.06% | 0.00% | Not reported | Q2 2022 | |
| $110K | 0.05% | 0.00% | +814.3% | Q1 2018 | |
| $105K | 0.05% | 0.00% | Not reported | Q2 2024 | |
| $88K | 0.04% | 0.00% | Not reported | Q2 2025 | |
| $86.6K | 0.04% | 0.00% | Not reported | Q4 2024 | |
Premium opens every quarter this fund has filed